(Contact: Email: zhengl@bjmu.edu.cn）

Deputy Director of Cardiovascular Research Institute, Peking University, Member of the Party Committee of School of Basic Medical Sciences, Peking University, Boya Distinguished Professor; Assistant Director of the National Key Laboratory, Deputy Director of the Department of Cardio-Cerebrovascular and Metabolism, School of Basic Medical Sciences. National Leading Talent for S&T Innovation (10,000 Talents Program); National Top Young Talent; Recipient of NSFC Excellent Young Scientists Fund; "New Century Talents" Talent Fund of Ministry of Education. As the first completer, he won the first prize of the 2022 Beijing Medical Science and Technology Award and the second prize of the 2022 Beijing Science and Technology Award. As principal investigator, he has led eight projects funded by the National Natural Science Foundation of China (NSFC), including major programs in vascular research; led or participated in six major national projects funded by the Ministry of Science and Technology; and directed three projects supported by the Beijing Municipal Natural Science Foundation, including key programs and the Beijing–Tianjin–Hebei Joint Fund. He was named to the 2025 World’s Top 2% Scientists list for annual scientific impact.

Director of Cardiometabolism and Proteomics Laboratory (PI), Professor, doctoral supervisor, major in cardiovascular pathophysiology. He graduated from the Department of Chemistry of Beijing Normal University. After graduation, he worked at the Institute of Physics and Chemistry, Chinese Academy of Sciences. In 2000, he studied for a Doctor of clinical bioanalytical chemistry in the Cleveland Clinic, which is the first cardiology department in the United States. After graduation, he worked for a biomedical company affiliated with Cleveland Hospital. In 2007, he joined the Institute of Cardiology, Peking University, as an associate professor and director of the Research Office as one of the "985" introduced talents. In 2014, he served as a doctoral supervisor and a member of the Party Committee of the School of Basic Medical Sciences. In 2015, he served as a researcher (Zhenggao) and doctoral supervisor in the School of Basic Medical Sciences, Peking University. In 2018, he served as the Deputy Director of the Cardiovascular Research Institute and the assistant Director of the Key Laboratory. In 2024, he served as a Peking University Boya Distinguished Professor and a tenured full professor under the new system. Currently, he is a member of the Basic Science Group of the Cardiovascular Society of the Chinese Medical Association, the vice chairman of the Precision Medicine Branch of the Chinese Society of Cardiothoracic Vascular Anesthesia, the Group leader of the Glucose and Lipid Metabolism Group of the Vascular Branch of the Beijing Physiological Association, the member of the Cardiovascular Pharmacology Committee of the Chinese Pharmacological Society, and the member of the Lipid and Lipoprotein Committee of the Chinese Pharmacological Society. He was the vice chairman of the Cardiovascular Evidence-based and Precision Medicine Committee of the Chinese Research Hospital Association, and the youth vice chairman of the Chinese Lipid and Lipoprotein Committee. A total of 143 SCI articles were published, of which 105 were SCI principal authors and cited more than 7880 times in SCI (h-index 46). ResearchGate (https://www.researchgate.net/profile/Lemin-Zheng). Main author articles (including common corresponding authors) are as follows: 33 articles with an Impact Factor (IF) ≥ 10, and 10 articles with an IF ≥ 20.

1) Cardiovascular and cerebrovascular diseases：European Heart Journal (IF=45.3, 2021); Circulation Research(IF=18.0, 2026); Neuron（IF=16.9, 2023）；Nature Communications（IF=18.1, 2025，2022）; Advanced Science（IF=14.1, 2025, 2023, 2022, 2021）; Cardiovascular Research（IF=12.5, 2021a, 2021b）; Science Bulletin（IF=20.7, 2025, 2023）; iMeta(IF=44.4, 2025a, 2025b, 2024, 2023) ;EMBO Molecular Medicine（2026）； Stroke（2022, 2021）; Circulation: Heart Failure（2021）; European Heart Journal Open（2022）; Arteriosclerosis, Thrombosis, and Vascular Biology（2019）; Aging Cell（2018）; Redox Biology（IF=16.2, 2021, 2018, 2017）; Cell Death & Disease（IF=12.2, 2018）.             

2) Metabolic-related diseases category: Signal transduction and targeted therapy（IF=81.2, 2023，2024）；Cell Metabolism（IF=37.0, 2023）; Journal of Clinical Investigation（IF=14.3, 2026, 2004）; Gastroenterology（IF=29.7, 2020）; Kidney International（IF=21.8, 2021）; Research(IF=12.9, 2025); Diabetes（IF=9.3, 2021）; Molecular Cancer（IF=42.2, 2014）; Clinical Cancer Research（IF=10.9, 2012）.

3) Research on Cardiovascular and Cerebrovascular Translational Medicine: Advanced Materials (IF = 26.8, 2020); Advanced Functional Materials (IF = 19.0, 2024, 2020, 2017); Nano Letters (IF = 9.1, 2021); Biosensors and Bioelectronics (IF = 11.9, 2022); Nano Research (IF = 9.0, 2020).

In 2010, He obtained invention patents granted by the USPTO and EPO From 2019 to 2024, a total of 8 Chinese patents were obtained (as the first inventor). From 2014 to 2020, registration certificates for clinical medical testing kits were approved (as the chief scientist). In 2022, the English monograph "HDL Metabolism and Diseases" was published by Springer Nature Publishing House. In 2026, he contributed to the Springer Nature monograph "Metabolomics and Precision Medicine" . He serves as an Associate Editor of Frontiers in Cardiovascular Medicine, View Medicine (Wiley), and The Journal of Cardiovascular Aging, and as an Editorial Board Member of several SCI-indexed journals, including iMeta, Genes & Diseases, Biology, and Cardiovascular Drugs and Therapy. He also founded the international journal Global Translational Medicine (GTM) and serves as its founding Editor-in-Chief

(https://www.accscience.com/journal/GTM).

Research directions:

1. Study on the impact of metabolic pathways on the homeostasis and disease mechanisms of the heart and brain. The functional homeostasis of the heart and blood vessels is closely related to their metabolic state. Metabolic pathways are widely involved in the occurrence and development of cardiovascular and cerebrovascular diseases (such as aneurysms, myocardial infarction, stroke, etc.). Metabolic regulation is an important research field following gene regulation and protein regulation. The team has discovered that multiple metabolic molecules and pathways are involved in new pathophysiological mechanisms of cardiovascular diseases and their key target proteins, including macrophages activating inflammatory responses by releasing succinate; cell junction protein Cx43 maintaining the homeostasis of the cerebral vascular endothelial barrier through regulating NAD+ levels; smooth muscle cells mediating the release of putrescine and phenotypic transformation under aneurysm conditions; lipid metabolism pathways such as apo(a) and lipid lipoprotein signaling pathways affecting the new mechanisms of the cardiovascular system, etc.

2. Discover new active factors from endogenous and gut microbiota sources and their metabolic regulatory effects. In samples from patients with cardiovascular and cerebrovascular diseases, we have identified multiple active factors through multi-omics methods, and discovered their effects and mechanisms on metabolic-related diseases such as diabetes, fatty liver, and tumors. Among them, we have confirmed that the endogenous factor annexin A1 plays a role in different cell types in aneurysm, diabetic nephropathy, and obesity and exerts protective effects, and vascular endothelial metabolism regulates angiogenesis and tumor progression in tumors. The gut microbiota is another important source of human metabolism. The metabolic spectrum changes caused by the disorder of the gut microbiota during the disease process further affect the disease progression, thereby generating new theoretical systems such as the gut-heart axis, gut-brain axis, and gut-liver axis. The team has first identified the new gut microbiota metabolite trimethylaminopropionic acid (TMAVA) and clarified its mechanism of aggravating fatty liver and cardiac hypertrophy, and has developed a mass spectrometry detection method for the important gut microbiota active metabolite trimethylamine (TMAO) and discovered its new pathophysiological functions in stroke and pulmonary arterial hypertension. Through metabolic intervention and metabolic-related regulation, we have proposed new ideas and insights for the treatment of cardiovascular and cerebrovascular diseases and metabolic-related diseases.

3. Conduct translational medical research on cardiovascular and cerebrovascular diagnosis and treatment using new materials and technologies. Use new technologies to develop diagnostic and treatment methods for cardiovascular and cerebrovascular diseases, including using bio-nanomaterials carrying imaging groups or pharmacological components to achieve non-invasive imaging or targeted treatment of diseases such as arterial plaques, using molecular probes and structure prediction to develop drugs to correct metabolic disorders related to diseases, optimizing clinical mass spectrometry detection methods to develop a multi-index comprehensive early warning system for cardiovascular and cerebrovascular diseases, etc., to help cardiovascular and cerebrovascular diagnosis and treatment continue to develop on a new track.

Forty represent SCI theses (*Author responsible):

1. Yufei Wu# , Xiaomei Yang# , Yu Bai , Chenze Li , Peng Wang , Qing Xu, Hui Li, Xiaoli Rao , Yangkai Xu , Jie Chen , Huanhuan Cao , Qi Zhang , Mingming Zhao, Rui Zhan , Xue Fan, Yuedong Hou , Jie Liu, Hong S. Lu , Tianyun Wang, Wei Dong Gao , Linzhang Huang, Han Xiao, Lingyun Zu , Alan Daugherty , *Mingguo Xu, *Lemin Zheng. Microvascular endothelial scavenger receptor class B type I protects against heart failure with preserved ejection fraction by inhibiting T-cell cardiotropism. EMBO Mol Med. 2026 May;18(5):1679-1706. (JCR=Q1)

2. Jiangtao Li#, Shusi Ding#, Zhao Yang , Mingdan Wang , Xuan Deng, Xueting Sun, Wenting Lu,Pingping Jia, Yan Liu, Yuhan Zhang, Jun Cai,*Lemin Zheng, *Yue Qi, and *Jing Liu. Metabolomic Profiles and Changes During the 20 Years Preceding Heart Failure. Circulation Research. 2026 Jul 24. doi: 10.1161/CIRCRESAHA.126.328542. Epub ahead of print. PMID: 42495742.(IF=18.0, JCR=Q1)

3. Pengxiang Qu#, Shusi Ding#, Yanru Zhang#, Yang Zhao,Erfei Song,Liangshuo Hu,Ruike Ding,Wenbin Cao,Yiting Hou, Jia Qi, Juan Zhao, Chenjing Duan, Shuangqing Liu, Chong Shen,Ying Zhao,Yanhong Guo,Zuowen Zheng, Shiwei Luo,Huizhong Hu,Liang Bai,Sihai Zhao,Bo Wang,Shuixiang He,Yi Wu,Xuelian Xiong,Qiutong Wu, Weiwang Gu,Oren Rom,Aimin Xu,*Lemin Zheng,*Jifeng Zhang,*Enqi Liu, and *Y. Eugene Chen.Metabolic dysfunction-associated steatohepatitis exacerbated by Clostridium perfringens-derived ammonia is attenuated by tripeptide DT-109. Journal of Clinical Investigation. 2026 May 12;136(13):e200522.  (IF=14.3, JCR=Q1)

4. Cheng Cui #, Lu Fang #, Lei Li#, Xuan Lai , Ruitao Zhang , Qi Zhang, Rong Miao, Gaofei Hu, Miao Zhang , Jie En Valerie Sia , Jingcheng Chen , Haodi Chai , Xinyi Wu, Zijin Lin, Fan Zhang , Haiyan Li , *Lemin Zheng , *Dongyang Liu. Odoribacter splanchnicus rescues aging-related intestinal P-glycoprotein damage via GDP-L-fucose secretion. Nature Communications. 2025 Nov 27;16(1):10665. (IF=15.7, JCR=Q1)

5. Nana Yang#, Jiahong Chen#, Yujie Zhu#, Wenxin Shan, Zheng Cao, Yiwen Fu, Huanhuan Cao, Yanyan Li, Yukun Xiang, Shusi Ding, Huiqing Wang, Yaobo Zhao, Liang Ji, Rui Zhan, Yufei Wu, Zhaomeng Wang,*Manyuan Dong, *Lemin Zheng. Human cardiac organoid model reveals antibacterial triclocarban promotes myocardial hypertrophy by interfering with endothelial cell metabolism. Science Bulletin. 2025 Feb 15;70(3):342-346. (IF=21.1, JCR=Q1)

6. Shilun Wu#, Changyu Yao#, Lu Fang#, Yiwen Sun, Mingming Zhao, Jie Chen, Gaofei Hu, Zhe Zhao, Shusi Ding, Jing Xue, Xiaoyi Liu, *Wenbing Su, *Jian Kong, *Lemin Zheng. ATPase Inhibitory Factor 1 Drives Mitochondrial Energy Metabolic Reprogramming to Promote HCC Vasculogenic Mimicry via the ESR1/miR-20a-3p/GNAZ Pathway. Research (Wash D C). 2025 Nov 25;8:0998. (IF=10.9, JCR=Q1)

7. Ling Chen#, Yujie Zhu#, Xi Yang, JiangBin Wu, Keyuan Chen, Wuqing Huang, Lu Fang, Qi Zhang, Jie Chen, Jianing Gao, Huanhuan Cao, Meifang Wu, Zhihuang Qiu, Yuling Zhang, Yue Shen, Qiuyu Huang, Zhiyong Lin, *Lemin Zheng, *Liangwan Chen. Leptin Aggravates Thoracic Aortic Dissection Through Impairment of Energy Metabolism in Nrip2+ Smooth Muscle Cells. Advanced Science (Weinh). 2025 Jul 16:e02027. (IF=14.1, JCR=Q1)

8. Luyun Fan#,Junru Chen#,Qi Zhang#,Jie Ren#,Youren Chen#, Jinfeng Yang#, Lu Wang#, Zihong Guo, Peili Bu, Bingpo Zhu, Yanyan Zhao, Yang Wang, Xiaoyan Liu, Wenjie Wang, Zhenzhen Chen, Qiannan Gao,*Lemin Zheng,*Jun Cai. Fecal microbiota transplantation for hypertension: an exploratory, multicenter, randomized, blinded, placebo-controlled trial. Microbiome.2025 May 23;13(1):133. (IF=13.8, JCR=Q1)

9. Chengjun Zheng#, Peng Wang#, Delong Zhang#, Zheng Fang, Yutong Feng, Jie Chen, Jiahong Chen, Yiwen Fu, Bao Yang, Shuqing Yu, Li Min, Bo Xiao, Cencan Xing, Yang Yang, Jianfeng Wang, Donghua Zou, Shipeng Ning, Tong Liu, Jun Yan, Qian Zhao, Fei Sun, Qiaodong Chen, Ying Zhang, *Tao Jiang, *Lemin Zheng, *Zhaoshi Bao. A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation. Bioactive Materials. 2025 Jul 14;53:205-217.(IF=20.3, JCR=Q1)

10. Zhe Zhao, Jing Chen, Yixuan Liu, Shiqi Wang, Danhua Zhao, Chaobo Bai, Meifang Wu, Gaofei Hu, Yiwen Fu, Lu Fang, Xiaoyi Liu, Zheng Zhang, Rui Zhan, *Lemin Zheng, *Junliang Yuan. Multi-omics identifies microbiota-derived deoxycholic acid as a key mediator of blood-brain barrier dysfunction in Parkinson’s disease. iMeta. 2025 Sep 17;4(5):e70076. . (IF=44.4, JCR=Q1)

11. Xu Lin#, Zuxiang Yu#, Yang Liu#, Changzhou Li#, Hui Hu#, Jia-Chun Hu#, Mian Liu#, Qin Yang, Peng Gu, Jiaxin Li, Kutty Selva Nandakumar, Gaofei Hu, Qi Zhang, Xinyu Chen, Huihui Ma, Wenye Huang, *Gaofeng Wang, *Yan Wang, *Liping Huang, *Wenjuan Wu, *Ning-Ning Liu, *Chenhong Zhang, *Xingyin Liu, *Lemin Zheng, *Peng Chen. Gut-X axis. iMeta. 2025 Feb 26;4(1):e270. (IF=44.4, JCR=Q1)

12. Lu Fang#, Changjie Liu#, Zong-Zhe Jiang, Mengxiao Wang, Kang Geng, Yangkai Xu, Yujie Zhu, Yiwen Fu, Jing Xue, Wenxin Shan, Qi Zhang, Jie Chen, Jiahong Chen, Mingming Zhao, Yuxuan Guo, K W Michael Siu, Y Eugene Chen, *Yong Xu, *Donghui Liu, *Lemin Zheng. Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesity. Signal transduction and targeted therapy. 2024 Aug 23;9(1):218. (IF=52.7, JCR：Q1)

13. Jiageng Cai#, Xiaoxiao Ge#, Shiyu Lu, Yabin Wang, Hongtu Cui, Rui Zhan, Sheng'e Su, Wenxin Shan, Zhulan Cai, Cencen Wu, Yuan Xu, Penghui Zhao, Yanyan Li, Yue Lan, Le Sun, *Shaojun Guo, *Lemin Zheng, *Lingyun Zu. Au/FeNiPO4-Based Multiple Spectra Optoacoustic Tomography/CT Dual-Mode Nanoprobe for Systemic Screening of Atherosclerotic Vulnerable Plaque. Advanced Functional Materials. 2024 May 29. (IF=19.0, JCR=Q1)

14. Rui Zhan#, Xia Meng#, Dongping Tian, Jie Xu, Hongtu Cui, Jialei Yang, Yangkai Xu, Mingming Shi, Jing Xue, Weiwei Yu, Gaofei Hu, Ke Li, Xiaoxiao Ge, Qi Zhang, Mingming Zhao, Jianyong Du, Xin Guo, Wenli Xu, Yang Gao, Changyu Yao, Fan Chen, Yue Chen, Wenxin Shan, Yujie Zhu, Liang Ji, Bing Pan, Yan Yu, Wenguang Li, Xuyang Zhao, Qihua He, Xiaohui Liu, Yue Huang, Shengyou Liao, Bin Zhou, Dehua Chui, Y Eugene Chen, Zheng Sun, *Erdan Dong, *Yongjun Wang, *Lemin Zheng. NAD+ rescues aging-induced blood-brain barrier damage via the CX43-PARP1 axis. Neuron. 2023 Aug 29:S0896-6273(23)00622-0. (IF=15.0, JCR=Q1)

15. Pengxiang Qu#, Oren Rom#, Ke Li#, Linying Jia, Xiaojing Gao, Zhipeng Liu, Shusi Ding, Mingming Zhao, Huiqing Wang, Shuangshuang Chen, Xuelian Xiong, Ying Zhao, Chao Xue, Yang Zhao, Chengshuang Chu, Bo Wen, Alexandra C. Finney, Zuowen Zheng, Wenbin Cao, Jinpeng Zhao, Liang Bai, Sihai Zhao, Duxin Sun, Rong Zeng, Jiandie Lin, Wanqing Liu, *Lemin Zheng, *Jifeng Zhang, *Enqi Liu, Y. *Eugene Chen. DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. Cell Metabolism. 2023 May 2;35(5):742-757.e10. (IF=30.9, JCR=Q1)

16. Zekun Wang#, Nana Yang#, Yajun Hou, Yuqing Li, Chenyang Yin, Endong Yang, Huanhuan Cao, Gaofei Hu, Jing Xue, Jialei Yang, Ziyu Liao, Weiyun Wang, *Dongdong Sun, *Cundong Fan, *Lemin Zheng. L-Arginine-Loaded Gold Nanocages Ameliorate Myocardial Ischemia/Reperfusion Injury by Promoting Nitric Oxide Production and Maintaining Mitochondrial Function. Advanced Science (Weinh). 2023 Sep;10(26):e2302123. (IF=14.3, JCR=Q1)

17. Jianing Gao#, Huanhuan Cao, Gaofei Hu, Yufei Wu, Yangkai Xu, Hongtu Cui, Hong S Lu, *Lemin Zheng. The mechanism and therapy of aortic aneurysms. Signal transduction and targeted therapy. 2023 Feb 3;8(1):55. (IF=52.7, JCR=Q1)

18. Qingyuan Liu#, Ke Li#, Hongwei He, Zengli Miao, Hongtu Cui, Jun Wu, Shusi Ding, Zheng Wen, Jiyuan Chen, *Xiaojie Lu, *Jiangan Li, *Lemin Zheng, *Shuo Wang. The markers and risk stratification model of intracranial aneurysm instability in a large Chinese cohort. Science Bulletin. 2023 May 10:S2095-9273(23)00308-0. (IF=21.1, JCR=Q1)

19. Huanhuan Cao, Yujie Zhu, Gaofei Hu, Qi Zhang, *Lemin Zheng. Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis? Pharmacological Research. 2023 Jan;187:106586. (IF=10.5, JCR=Q1)

20. Mingming Zhao#, Haoran Wei#, Chenze Li, Rui Zhan, Changjie Liu, Jianing Gao, Yaodong Yi, Xiao Cui, Wenxin Shan, Liang Ji, Bing Pan, Si Cheng, Moshi Song, Haipeng Sun, Huidi Jiang, Jun Cai, Minerva Garcia-Barrio, Y. Eugene Chen, Xiangbao Meng, Erdan Dong, *Dao Wen Wang, *Lemin Zheng. Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nature Communications. 2022 Apr 1;13(1):1757. (IF=15.7, JCR=Q1)

21. Jianing Gao#, Yanghui Chen#, Huiqing Wang, Xin Li, Ke Li, Yangkai Xu, Xianwei Xie, Yansong Guo, Nana Yang, Xinhua Zhang, Dong Ma, Hong S Lu, Ying H Shen, Yong Liu, Jifeng Zhang, Y Eugene Chen, Alan Daugherty, *Dao Wen Wang, *Lemin Zheng. Gasdermin D Deficiency in Vascular Smooth Muscle Cells Ameliorates Abdominal Aortic Aneurysm Through Reducing Putrescine Synthesis. Advanced Science (Weinh). 2022 Dec 25:e2204038. (IF=14.3, JCR=Q1)

22. Yang Y#, Zeng Q#, Gao J#, Yang B, Zhou J, Li K, Li L, Wang A, Li X, Liu Z, Luo Q, Zhao Z, Liu B, Xue J, Jiang X, Konerman MC, * Zheng L, *Xiong C. High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. European Heart Journal Open. 2022 Mar 29;2(5):oeac021.

23. Xu J#, Hao X#, Zhan R#, Jiang X, Jin A, Xue J, Cheng A, Liu J, Lin J, Meng X, Li H, *Zheng L, *Wang Y. Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels. Stroke. 2022 Aug;53(8):2504-2511. (JCR=Q1)

24. Xiao-Xiao Chen#, Yufei Wu#, Xiaoxiao Ge, Liandi Lei, *Li-Ya Niu, *Qing-Zheng Yang, *Lemin Zheng. In vivo imaging of heart failure with preserved ejection fraction by simultaneous monitoring of cardiac nitric oxide and glutathione using a three-channel fluorescent probe. Biosensors and Bioelectronics. 2022 Oct 15;214:114510.（IF=11.9, JCR=Q1）

25. Xu J#, Cheng A#, Song B, Zhao M, Xue J, Wang A, Dai L, Jing J, Meng X, Li H, *Zheng L, *Wang Y. Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes. Stroke. 2022 Apr;53(4):1207-1215. (JCR=Q1)

26. Cui H#, Chen Y#, Li K, Zhan R, Zhao M, Xu Y, Lin Z, Fu Y, He Q, Tang PC, Lei I, Zhang J, Li C, Sun Y, Zhang X, Horng T, Lu HS, Chen YE, Daugherty A, *Wang D, *Lemin Zheng. Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection. European Heart Journal. 2021 Nov 7;42(42):4373-4385. (IF=37.6, JCR=Q1)

27. Wu L#, Liu C#, Chang DY, Zhan R, Sun J, Cui SH, Eddy S, Nair V, Tanner E, Brosius FC, Looker HC, Nelson RG, Kretzler M, Wang JC, Xu M, Ju W, Zhao MH, *Chen M, *Lemin Zheng. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney International. 2021 Jul;100(1):107-121. (IF=12.6, JCR=Q1)

28. Jiang X, Xu J, Hao X, Xue J, Li K, Jin A, Lin J, Meng X, *Zheng L, *Wang Y. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A2 are associated with unfavorable functional outcomes in patients with ischemic stroke. Journal of Neuroinflammation. 2021 Dec 28;18(1):307. (IF=10.1, JCR=Q1)

29. Xu J#, Zhao M#, Wang A, Xue J, Cheng S, Cheng A, Gao J, Zhang Q, Zhan R, Meng X, Xu M, Li H, Zheng L*, Wang Y*. Association Between Plasma Trimethyllysine and Prognosis of Patients With Ischemic Stroke. Journal of the American Heart Association. 2021 Dec 7;10(23):e020979. (JCR=Q1)

30. Li C#, Zhao M#, Xiao L, Wei H, Wen Z, Hu D, Yu B, Sun Y, Gao J, Shen X, Zhang Q, Cao H, Huang J, Huang W, Li K, Huang M, Ni L, Yu T, Ji L, Xu Y, Liu G, Konerman MC, *Lemin Zheng, *Wang D. Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circulation: Heart Failure. 2021 Nov;14(11):e008459 （JCR=Q1）

31. Wu L#, Liu C#, Chang D Y, Zhan R, Zhao M, Lam S M, Shui G, Zhao M H, *Lemin Zheng, *Chen M. The attenuation of diabetic nephropathy by annexin A1 via regulation of lipid metabolism through AMPK/PPARα/CPT1b pathway. Diabetes. 2021 Oct;70(10):2192-2203. (JCR=Q1)

32. Zhou C, Lin Z, Cao H, Chen Y, Li J, Zhuang X, Ma D, Ji L, Li W, Xu S, *Pan B, *Lemin Zheng. Anxa1 in smooth muscle cells protects against acute aortic dissection. Cardiovascular Research. 2021 Mar 23:cvab109. (IF=13.3, JCR=Q1)

33. Jingxuan Li#, Yingyu Chen#, Jianing Gao, Yue Chen, Changping Zhou, Xin Lin, Changjie Liu, Mingming Zhao, Yangkai Xu, Liang Ji, Zongzhe Jiang, *Bing Pan, *Lemin Zheng. Eva1a ameliorates atherosclerosis by promoting re-endothelialization of injured arteries via Rac1/Cdc42/Arpc1b. Cardiovascular Research. 2021 Jan 21;117(2):450-461. (IF=13.3, JCR=Q1)

34. Jian Kong#, Changyu Yao#, Shuying Dong#, Shilun Wu, Yangkai Xu, Ke Li, Liang Ji, Qiang Shen, Qi Zhang, Rui Zhan, Hongtu Cui, Changping Zhou, Haigang Niu, Guoming Li, *Wenbing Sun, *Lemin Zheng. ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-cadherin after Insufficient Radiofrequency Ablation. Advanced Science (Weinh). 2021 Jan 4;8(4):2002228. (IF=14.3, JCR=Q1)

35. Man Z, Cui H, Lv Z, Xu Z*, Wu Z, Wu Y, Liao Q, Liu M, Xi P*, Zheng L*, Fu H*. Organic Nanoparticles-Assisted Low-Power STED Nanoscopy. Nano Letters. 2021 Apr 28;21(8):3487-3494. (JCR=Q1)

36. Zhang M#, Gao J#, Zhao X, Zhao M, Ma D, Zhang X, Tian D, Pan B, Yan X, Wu J, Meng X, Yin H, *Lemin Zheng. p38α in macrophages aggravates arterial endothelium injury by releasing IL-6 through phosphorylating megakaryocytic leukemia 1. Redox Biology. 2021 Jan;38:101775. (IF=11.9, JCR=Q1)

37. Mingming Zhao#, Lin Zhao#, Xuelian Xiong, Yuan He, Wei Huang, Zihao Liu, Liang Ji, Bing Pan, Xuefeng Guo, Leibo Wang, Si Cheng, Ming Xu, Hongyuan Yang, Yuxin Yin, Minerva T. Garcia-Barrio, Y. Eugene Chen, Xiangbao Meng, *Lemin Zheng. TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. Gastroenterology. 2020 Jun;158(8):2266-2281. (IF=25.1, JCR=Q1)

38. Xiaoxiao Ge#, Hongtu Cui#, Jian Kong, Shi-Yu Lu, Rui Zhan, Jianing Gao, Yangkai Xu, Shuangyan Lin, Kaixin Meng, Lingyun Zu, Shaojun Guo, *Lemin Zheng. A Non-Invasive Nanoprobe for In Vivo Photoacoustic Imaging of Vulnerable Atherosclerotic Plaque. Advanced Materials. 2020 Sep;32(38):e2000037. (IF=26.8, JCR=Q1)

39. Zheng Lv#, Zhongwei Man#, Hongtu Cui, Zhenzhen Xu*, Huanhuan Cao, Shuai Li, Qing Liao, Qihua He, Lemin Zheng*, and Hongbing Fu*. Red AIE Luminogens with TunableOrganelle Specific Anchoring for Live Cell Dynamic Super Resolution Imaging. Advanced Functional Materials. 2020, 31(10), 2009329. (IF=19.0, JCR=Q1)

40. He D#, Zhao M#, Wu C, Zhang W, Niu C, Yu B, Jin J, Ji L, Willard B, Mathew A, Chen Y, Pennathur S, Yin H, He Y, *Pan B, *Lemin Zheng. Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1. Redox Biology. 2018 May;15:228-242. (IF=11.9, JCR=Q1)

As a supervisor in training doctoral students (including co-supervisors), won awards:

Fang Lu (Ph.D. student, 2025, Zheng Leimin as supervisor); Outstanding Graduate of Beijing; Outstanding Graduate of Peking University.

Gao Jianing (Ph.D. student, 2023, Zheng Leimin as supervisor): "Outstanding Doctoral Student" of Peking University.

Wu Qing (Ph.D. student, 2022, Zheng Leimin as co-supervisor): "Outstanding Doctoral Student" of Beijing; "Outstanding Doctoral Student" of Peking University.

Cui Hongtu (Ph.D. student, 2021, Zheng Leimin as supervisor): Outstanding Graduate of Beijing; Outstanding Graduate of Peking University; Recipient of the "Postdoctoral Program for Elite Scholars of China"; currently an associate researcher at Peking University Third Hospital.

Yao Changyu (Ph.D. student, 2021, Zheng Leimin as co-supervisor): "Outstanding Doctoral Student" of Beijing; "Outstanding Doctoral Student" of Capital Medical University. Awarded "Beijing Science and Technology Star" in 2026.

Zhao Mingming (Ph.D. student, 2020, Zheng Leimin as supervisor): Outstanding Graduate of Beijing; "Outstanding Doctoral Student" of Peking University; Outstanding Graduate of Peking University; Recipient of the "Postdoctoral Program for Elite Scholars of China". Currently an associate researcher at Peking University Third Hospital.

Postdoctoral training award:

Zhan Rui (Postdoctoral, 2022, with Zheng Leimin as the co-supervisor); "Young Taishan Scholar" of Shandong Province (2024); Currently a doctoral supervisor at Rehabilitation University.